Efficacy and Safety of Selexipag Treatment in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease.

Chebly Dagher, Maria Akiki, Kristen Swanson, Brett Carollo, Harrison W Farber, Raj Parikh

Abstract read

In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chebly DagherDepartment of Internal Medicine, University of Connecticut, Farmington, CT 06030, USA.ORCID 0009-0003-2377-7859

Maria AkikiDepartment of Internal Medicine, University of Connecticut, Farmington, CT 06030, USA.

Kristen SwansonDivision of Pulmonary, Critical Care and Sleep, Hartford Hospital, Hartford, CT 06102, USA.

Brett CarolloDivision of Pulmonary, Critical Care and Sleep, Hartford Hospital, Hartford, CT 06102, USA.

Harrison W FarberDivision of Pulmonary, Sleep and Critical Care Medicine, Tufts Medical Center, Boston, MA 02111, USA.

Raj ParikhDivision of Pulmonary, Critical Care and Sleep, Hartford Hospital, Hartford, CT 06102, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) and concomitant interstitial lung disease (ILD) are particularly challenging to manage due to concerns about ventilation-perfusion mismatch with systemic vasodilators. In this case series, we evaluated the effects of selexipag in eight prostacyclin-naïve CTD-PAH patients with concomitant ILD. Clinical, functional, and laboratory data were collected at baseline and after 16 weeks of treatment. After 16 weeks of treatment, the mean six-minute walk distance increased by 101.75 m (

Indexed as

connective tissue diseaseinterstitial lung diseasepulmonary hypertensionselexipagventilation–perfusion mismatch

Identifiers

PMID40566626

DOI10.3390/life15060974

PMCPMC12194360

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.